Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: A 10-year history with a recent response to infliximab

Clinical and Experimental Dermatology

Volumn 33, Issue 2, 2008, Pages 156-159

  Marzano, A V ^a   Tourlaki, A ^a   Alessi, E ^a   Caputo, R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN A; DAPSONE; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

ADULT; ANAMNESIS; ARTICLE; AUTONOMIC DYSFUNCTION; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MONITORING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESCHERICHIA COLI; FOLLOW UP; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SKIN BIOPSY; SKIN ULCER; STAPHYLOCOCCUS AUREUS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; DRUG RESISTANCE, BACTERIAL; HUMANS; MALE; PYODERMA GANGRENOSUM; SKIN ULCER; TREATMENT OUTCOME;

EID: 38849117028     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2007.02607.x     Document Type: Article

References (10)

1. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma gangrenosum. Clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol 1930 22 : 655 80.
2. Crowson AN, Mihm MC Jr., Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003 30 : 97 107.
3. Ahmadi S, Powell FC. Pyoderma gangrenosum: uncommon presentations. Clin Dermatol 2005 23 : 612 20.
4. McGowan JW IV., Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 2004 3 : 441 4.
5. Wilson-Jones E, Winkelmann RK. Superficial granulomatous pyoderma. A localized vegetative form of pyoderma gangrenosum. J Am Acad Dermatol 1988 18 : 511 21.
6. Jenne L, Sauter B, Thumann P et al. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody). Br J Dermatol 2004 150 : 380 2.
7. Skapenko A, Niedobitek GU, Kalden JR et al. Generation and regulation of human Th1-biased immune responses in vivo: a critical role for IL-4 and IL-10. J Immunol 2004 172 : 6427 34.
8. Brooklyn TN, Dunnill MG, Shetty A et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006 55 : 505 9.
9. Kaur MR, Lewis HM. Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol 2005 153 : 689 91.
10. Louis M, Rauch J, Armstrong M, Fitzcharles M. Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 2003 30 : 2557 62.